menu
    • menu
    [{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APG333","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APG808","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"APG808","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Apogee Therapeutics

    Menu

    Apogee Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

                            Details : APG777 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 18, 2025

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

                            Details : APG777 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 04, 2025

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Shows Interim Success in Phase 1b Trial of APG808 for Asthma

                            Details : APG808 is a novel half-life extended IL-4Rα antibody, which is currently being evaluated for the treatment of mild-to-moderate asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults Wi...

                            Details : APG777 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : APG777

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee's APG990 Phase 1 Shows Potential for 3- & 6-Month Maintenance Dosing

                            Details : APG990 is a novel, SQ, half-life extended mAb targeting OX40L

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Patient in Part B of Phase 2 APEX Trial for APG777 in Atopic Dermatitis

                            Details : APG777 is a IL-13 inhibitor antibody candidate, which is being evaluated in clinical trial studies for the treatment of patients with atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG333

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Participants in Phase 1 APG333 Trial for Respiratory Conditions

                            Details : APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions, like asthma, COPD.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : APG333

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Therapeutics Begins Phase 1 Trial of APG990 for Inflammatory Diseases

                            Details : APG990 is a novel, SQ half-life extended monoclonal antibody which works by targeting OX40L, it is currently being developed for Atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating APG777 in Atopic Dermatitis

                            Details : APG777 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 02, 2024

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Patients in APG808 Phase 1 for COPD and Inflammatory Diseases

                            Details : APG808 is a novel subcutaneous extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed for people living with moderate-to-severe COPD, asthma and other I&I diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth